

# The use of perioperative n-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass

<b>Submission date</b> 10/05/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 05/07/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 12/11/2007	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Karen Burns

**Contact details**  
375 South Street  
London  
Canada  
N6A 4G5

## Additional identifiers

### Study information

Scientific Title

Study objectives

To determine whether perioperative intravenous (IV) N-acetylcysteine preserves renal function in high-risk patients undergoing Coronary Artery Bypass Graft (CABG) surgery with Cardiopulmonary Bypass (CPB) compared with placebo.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Prevention

**Health condition(s) or problem(s) studied**

Coronary artery bypass graft surgery

**Interventions**

We randomized patients to receive four (two intraoperative and two postoperative) doses of intravenous N-acetylcysteine 600 mg or placebo over a 24-hour period.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Intravenous N-acetylcysteine

**Primary outcome(s)**

The primary outcome was the proportion of patients developing postoperative renal dysfunction, defined by an increase in serum creatinine level greater than 0.5 mg/dL (44 micromol/L) or a 25% increase from baseline within the first 5 postoperative days.

**Key secondary outcome(s)**

Secondary outcomes included postoperative interventions and complications, the requirement for renal replacement therapy (RRT), adverse events, hospital mortality, and ICU and hospital length of stay.

**Completion date**

01/09/2004

**Eligibility**

**Key inclusion criteria**

Elective or urgent coronary artery bypass graft surgery patients with at least one of: pre-existing renal dysfunction, age greater than or equal to 70, diabetes mellitus, impaired left ventricular function or undergoing concomitant valve or redo surgery.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Senior

**Sex**

All

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/10/2003

**Date of final enrolment**

01/09/2004

**Locations****Countries of recruitment**

Canada

**Study participating centre**

375 South Street

London

Canada

N6A 4G5

**Sponsor information****Organisation**

The Physician Services Incorporated Foundation (Canada)

**ROR**

<https://ror.org/0385yzn06>

# Funder(s)

## Funder type

Charity

## Funder Name

The Physician Services Incorporated Foundation (Canada)

## Funder Name

The Lawson Health Research Institute Internal Research Fund (Canada)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	20/07/2005		Yes	No